Ana C.
- Country
- Sweden
- Department
- Klinisk Forskningsenhet, VE Onkologi, VO Hematologi, Onkologi och Strålningsfysik
Research Overview
- Biomarker-Driven Targeted Therapy in Advanced Cancer: A Swedish Nationwide Clinical Trial (FOCU.SE)
- Phase 1/2 Open‑Label Study of Oral GSK5460025A Monotherapy and Combination Therapy Assessing Safety and Efficacy in dMMR/MSI‑H Tumors, colorectal and endometrial cancer
- Phase 1/2 Open‑Label Study of RAS(ON) Inhibitor RMC-6291 with ivonescimab ± combination therapy in patients with advanced RAS‑mutated solid tumors
Data & Insights
Has run more than one trial at 81 of 201 partner sites.
Specializations
Melanoma Research Focus
The investigator specializes in treating various forms of melanoma, with particular expertise in managing both early and advanced stages of the disease. Their research encompasses previously untreated metastatic melanoma, uveal melanoma liver metastases, and resectable stage III melanoma.
- Advanced and Metastatic Disease Management
- Neoadjuvant Treatment Approaches
- Post-surgical Therapeutic Strategies
Advanced Solid Tumors
The investigator conducts research on advanced solid malignancies with a focus on novel therapeutic approaches. Their work includes studies of various tumor types including breast cancer, ovarian cancer, and tumors with specific genetic markers such as BRAF alterations.
- Targeted Therapy Development
- Immunotherapy Combinations
- Biomarker-Driven Treatment
Innovative Treatment Approaches
The investigator explores cutting-edge therapeutic strategies including monoclonal antibody treatments and immune checkpoint inhibition. Their research includes investigation of novel drug combinations and treatment durations for optimal patient outcomes.
- Combination Immunotherapy
- Novel Drug Development
- Personalized Medicine Strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.